차백신연구소
Financials
Valuation Metrics
차백신연구소's Market Cap is ₩990B. At end of 2025 it was ₩818B. Ranked #1221 of 2,405 in KR market (top 51%), #656 of 1,627 on KOSDAQ (top 40%), #136 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 99.03B KRW | KR#1,221/2,405 Sec#136/231 |
| Revenue | 158.6M KRW | KR#2,377/2,405 Sec#223/231 |
| Net Income | -14.42B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 21.15B KRW | KR#2,363/2,405 Sec#226/231 |
| Net Assets | 9.89B KRW | KR#2,360/2,405 Sec#224/231 |
| Employees | 56 | KR#1,995/2,405 Sec#180/231 |
| Value | ||
| P/B | 10.01x | KR#2,354/2,405 Sec#213/231 |
| P/S | 624.33x | KR#2,394/2,405 Sec#225/231 |
| FCF Yield | -11.24% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -145.79% | KR#2,355/2,405 Sec#223/231 |
| ROA | -68.19% | KR#2,366/2,405 Sec#221/231 |
| Revenue Growth | -57.21% | KR#2,287/2,405 Sec#205/231 |
| Financial Health | ||
| Debt Ratio | 113.79% | KR#1,650/2,405 Sec#189/231 |
| Total Debt | 6.19B KRW | KR#1,735/2,405 Sec#164/231 |
| FCF | -11.13B KRW | KR#1,731/2,405 Sec#155/231 |
| Cash | 6.94B KRW | KR#1,878/2,405 Sec#168/231 |
| Current Ratio | 1.92x | KR#904/2,405 Sec#102/231 |
| Performance | ||
| 1Y Return | 25.50% | KR#279/2,405 Sec#18/231 |
| 1M Return | 0.29% | KR#311/2,405 Sec#34/231 |
| From 52W High | -49.11% | KR#1,136/2,405 Sec#90/231 |
| 1Y MDD | -67.42% | KR#1,827/2,405 Sec#154/231 |
| Trading | ||
| Volume | 152,025 shares | KR#473/2,405 Sec#50/231 |
| Trading Value | 508.2M KRW | KR#788/2,405 Sec#82/231 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/231 |
| Per Share | ||
| EPS | -498 KRW | KR—/2,405 Sec—/231 |
| BPS | 342 KRW | KR#2,388/2,405 Sec#229/231 |
Company Info
CHA Vaccine Institute, a bio venture company established in 2000, joined the CHA Hospital/CHA Bio Group in 2011 when CHA Biotech became its largest shareholder. Utilizing its independently developed immune-enhancing platform technology, the company is developing next-generation vaccines, including therapeutic vaccines for chronic Hepatitis B, and anti-cancer immunotherapeutics. Its immune enhancers boost immune responses to vaccine antigens; specifically, Lipo-pam® is ideal for therapeutic vaccine development due to its ability to induce strong cellular immune responses. CHA Vaccine Institute is headquartered in Seongnam-si, Gyeonggi-do.